State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
Abstract Objective To study the clinical significance of minimal residual disease (MRD) in B-lineage acute lymphoblastic leukemia (B-ALL) pediatric patients with different fusion gene backgrounds. Methods A retrospective analysis was performed on the medical data of 441 B-ALL children who were treated from January 2008 to April 2015. Among the 441 children, 336 had negative fusion gene, 79 had positive ETV6-RUNX1 fusion gene, and 26 had positive E2A-PBX1 fusion gene. Flow cytometry was used to detect MRD, and the influence of MRD on day 15 (TP1), day 33 (TP2), and week 12 (TP3) of induction therapy on prognosis was analyzed. Results In patients with negative fusion gene, the positive MRD group had significantly lower overall survival (OS) rate and event-free survival (EFS) rate (P < 0.05) and significantly higher recurrence rate and mortality rate at TP1, TP2, and TP3, compared with the negative MRD group (P < 0.05). In patients with positive ETV6-RUNX1, the positive MRD group had significantly lower OS and EFS rates (P < 0.05) and significantly higher recurrence rate and mortality rate (P < 0.05) than the negative MRD group only at TP1. In patients with positive E2A-PBX1, there were no significant differences in the OS rate, recurrence rate, and mortality rate between the positive and negative MRD groups at TP1, TP2, and TP3 (P > 0.05). Conclusions MRD has the most definite prognostic significance in pediatric B-ALL patients with negative fusion gene, while it has unsatisfactory prognostic significance in those with positive ETV6-RUNX1 or positive E2A-PBX1.
Dun KA, Vanhaeften R, Batt TJ, et al. BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1-positive B-cell acute lymphoblastic leukemia[J]. Blood Adv, 2016, 1(2):132-138.
[2]
Hong Y, Zhao X, Qin YZ, et al. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2018, 97(9):1547-1554.
[3]
Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia[J]. Blood, 2017, 129(3):347-357.
[4]
van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia:need for sensitive, fast, and standardized technologies[J]. Blood, 2015, 125(26):3996-4009.
Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008:the first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7):913-920.
Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry[J]. Cytometry B Clin Cytom, 2016, 90(1):47-53.
[11]
Polak R, Bierings MB, van der Leije CS, et al. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia[J]. Haematologica, 2019, 104(4):738-748.
[12]
Ampatzidou M, Papadhimitriou SI, Paterakis G, et al. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL):the spectrum of clonal heterogeneity and its impact on prognosis[J]. Cancer Genet, 2018, 224-225:1-11.
[13]
Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1[J]. Leukemia, 2009, 23(8):1406-1409.
Metzler M, Mann G, Monschein U, et al. Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia:comparison of Ig/TCR rearrangements and the genomic fusion gene[J]. Haematologica, 2006, 91(5):683-686.
[16]
Pui CH, Pei D, Raimondi SC, et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy[J]. Leukemia, 2017, 31(2):333-339.
[17]
Huang AJ, Huang CM, Tang GS, et al. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia[J]. Leuk Lymphoma, 2018, 59(5):1073-1083.
[18]
Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia:relation to other risk factors. A Children's Oncology Group study[J]. Leukemia, 2003, 17(8):1566-1572.
[19]
O'Connor D, Enshaei A, Bartram J, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia[J]. J Clin Oncol, 2018, 36(1):34-43.
[20]
Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?[J]. Leukemia, 2007, 21(4):622-626.
[1]
LI Lei, ZHANG Zhi-Quan, ZHENG Cheng-Zhong, SHI Yuan, Pediatric Disaster Branch of Chinese Pediatric Society of Chinese Medical Association, Pediatric Branch of Chinese People's Liberation Army. Expert consensus on the prevention and treatment of drowning in children[J]. CJCP, 2021, 23(1): 12-17.
